Zobrazeno 1 - 10
of 20
pro vyhledávání: '"David E. Allison"'
Publikováno v:
The AAPS Journal
Altered pharmacokinetics of antibody drugs has been reported in advanced gastric cancer (AGC). We aim to evaluate bevacizumab pharmacokinetics in AGC from the Phase III trial (AVAGAST), and explore the influence of patient variables. Bevacizumab conc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fe52bcaf14730c026f384a85219f33
https://doi.org/10.1208/s12248-014-9631-6
https://doi.org/10.1208/s12248-014-9631-6
Autor:
Patrick McKay, Liliana T Yee, Valerie Quarmby, Philip E. Hass, Xiangdan Wang, Kyra J. Cowan, Kevin Lin, George Dutina, David E. Allison, Jihong Yang, Ihsan Nijem
Publikováno v:
mAbs. 9(2)
Binding interactions with the neonatal Fc receptor (FcRn) are one determinant of pharmacokinetic properties of recombinant human monoclonal antibody (rhumAb) therapeutics, and a conserved binding motif in the crystallizable fragment (Fc) region of Ig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12df504587eb7de1e451964710180e76
https://pubmed.ncbi.nlm.nih.gov/28001487
https://pubmed.ncbi.nlm.nih.gov/28001487
Autor:
Kelong Han, Jin Jin, Michela Casanova, Sridharan Gururangan, Nathalie H. Gosselin, Jacques Grill, Johannes H. M. Merks, Fariba Navid, Angelica Quartino, David E. Allison, Najat C. Daw, Maura Massimino, Thomas Peyret
Publikováno v:
British journal of clinical pharmacology, 81(1), 148-160. Wiley-Blackwell
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology
Aim The aim of the present study was to evaluate the pharmacokinetics of bevacizumab and various dosing strategies for this agent in paediatric patients. Methods Data were collected from 232 paediatric patients (1971 concentrations) in five studies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1603b2bfc305e6c364d96995e0b4da
https://pure.amc.nl/en/publications/bevacizumab-dosing-strategy-in-paediatric-cancer-patients-based-on-population-pharmacokinetic-analysis-with-external-validation(f0785aab-17ae-48f8-8338-1917d769eaa4).html
https://pure.amc.nl/en/publications/bevacizumab-dosing-strategy-in-paediatric-cancer-patients-based-on-population-pharmacokinetic-analysis-with-external-validation(f0785aab-17ae-48f8-8338-1917d769eaa4).html
Publikováno v:
Pharmaceutical Research. 23:1275-1284
Our objectives were to develop the population pharmacokinetic (PK) for pertuzumab and examine the variability of steady-state trough serum concentrations (C SS,trough) and exposure after fixed, body-weight-based, or body-surface area (BSA)-based dosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98736b0f000259a516b7d317ff16075a
https://doi.org/10.1007/s11095-006-0205-x
https://doi.org/10.1007/s11095-006-0205-x
Autor:
Camellia W. Adams, Kelly Flagella, Janet Clarke, David E. Allison, Noel Dybdal, Kathleen McKeever, Mark X. Sliwkowski, Leonard G. Presta
Publikováno v:
Cancer Immunology, Immunotherapy. 55:717-727
Dimerization is essential for activity of human epidermal growth factor receptors (HER1/EGFR, HER2/ErbB2, HER3/ErbB3, and ErbB4) and mediates intracellular signaling events leading to cancer cell proliferation, survival, and resistance to therapy. HE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bfefddb146dca6dcafce7371e5eeb91
https://doi.org/10.1007/s00262-005-0058-x
https://doi.org/10.1007/s00262-005-0058-x
Autor:
Michael F. Press, Charles T. Taylor, Gracie Lieberman, David E. Allison, Michael S. Gordon, David S. Mendelson, Beth Y. Karlan, Stephen Michael Kelsey, David B. Agus, Ronald B. Natale, Gwen Fyfe, Mark X. Sliwkowski
Publikováno v:
Journal of Clinical Oncology. 23:2534-2543
Purpose Pertuzumab, a recombinant humanized monoclonal antibody (2C4), binds to extracellular domain II of the HER-2 receptor and blocks its ability to dimerize with other HER receptors. Pertuzumab represents a new class of targeted therapeutics know
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81ab347b559240a13bb751aeb0fc2e73
https://doi.org/10.1200/jco.2005.03.184
https://doi.org/10.1200/jco.2005.03.184
Publikováno v:
BioDrugs. 16:63-70
Background and Objectives: Leucocyte β2 integrin adhesion receptors are hypothesised as a therapeutic target to modify immune responses to ischaemia-reperfusion injury that may be detrimental to recovery in a variety of disease states. Two phase I s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fc59a1b87f8c43b45451dfcb17b8cee
https://doi.org/10.2165/00063030-200216010-00007
https://doi.org/10.2165/00063030-200216010-00007
Autor:
Deborah L. Baly, Richard Horuk, Daniel G. Yansura, Laura C. Simmons, Wayne J. Fairbrother, Claire Kotts, Cindy M. Wirth, Beth L. Gillece-Castro, Karen Toy, Joseph Hesselgesser, David E. Allison
Publikováno v:
The Journal of Immunology. 161:4944-4949
Melanoma growth stimulating activity (MGSA) and IL-8 are related chemokines that are potent chemoattractants and activators of neutrophils both in vitro and in vivo. Increasing evidence suggests that these molecules play an important role in inflamma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9392199817c1ce3d0f9d77231723b71
https://doi.org/10.4049/jimmunol.161.9.4944
https://doi.org/10.4049/jimmunol.161.9.4944
Publikováno v:
Cancer chemotherapy and pharmacology. 71(3)
The study characterizes the long-term pharmacokinetics (PK) following last dose of bevacizumab as adjuvant therapy in patients with resected stage II and III colon carcinoma in a Phase III clinical study (AVF3077s).Patients in AVF3077s received bevac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342e08e1aa6794b4bed7682dacda4ee7
https://pubmed.ncbi.nlm.nih.gov/23228985
https://pubmed.ncbi.nlm.nih.gov/23228985
Autor:
Mark J. Dresser, Denise Jin, Dan Lu, Yan Xin, Shuang Bai, Lisa A. Damico-Beyer, Karin Jorga, Manish Gupta, Yi Zhang, David E. Allison, Amita Joshi, Meina Tang, Yanan Zheng
Publikováno v:
Clinical pharmacokinetics. 51(2)
Dosing of therapeutic monoclonal antibodies (mAbs) is often based on body size, with the perception that body size-based dosing would reduce inter-subject variability in drug exposure. However, most mAbs are target specific with a relatively large th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a094689ecaab93ea34c19a5745f69383
https://pubmed.ncbi.nlm.nih.gov/22257150
https://pubmed.ncbi.nlm.nih.gov/22257150